The Leucegene project aims at paving the way for a new era in personalized medicine for patients suffering from acute myeloid leukemia (AML). The current sample cohort consists of 529 primary samples acquired and managed by the BCLQ among which 452 are AML samples with 373 samples classified as diagnostic AML samples (excluding acute promyelocytic leukemia(APL)).
For more details on how to cite the Leucegene Project, please refer to the FAQ section.
To access the data, browse the different sections of the Leucegene Data Portal. Note that Leucegene transcriptomic data was also deposited in the Gene Expression Omnibus (GEO).
A number of tools using Leucegene's data have been developed by the team. Among them:
  • Lasa, a web portal presenting the analysis and the data associated to the surfaceome.
  • SPAT, a tool that scores proteins according to the chance they have to be located at the cell surface
  • KM and KM-target, to identify events (mutations, insertions, ...) in sequences without mapping in a genome region of interest.
  • EPCY, to evaluate the predictive capability of a gene to become a predictive biomarker.
  • MiSTIC, an integrated platform for the analysis of heterogeneity in transcriptomes
  • HemoGene, who presents gene expression by blood cell lines